Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Cannon

Showing results (401-410 of 418) with videos related to

Pageof 42
Sort By:
Physiological Genomics|December 13, 2018
Identification of molecular signatures of cystic fibrosis disease status with plasma-based functional genomicsHara Levy, Shuang Jia, Amy Pan, et al.
JCO Precision Oncology|December 14, 2023
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry StudyFunda Meric-Bernstam, Michael Rothe, Pam K Mangat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2024
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With <i>ERBB2/3</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyTimothy L Cannon, Michael Rothe, Pam K Mangat, et al.
MMWR. Morbidity and Mortality Weekly Report|October 19, 2018
Notes from the Field: Contact Tracing Investigation after First Case of Andes Virus in the United States - Delaware, February 2018Aaron Kofman, Paula Eggers, Anne Kjemtrup, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2023
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry StudyHerbert L Duvivier, Michael Rothe, Pam K Mangat, et al.
Annals of the New York Academy of Sciences|January 31, 2023
Viral immunity: Basic mechanisms and therapeutic applications-a Keystone Symposia reportJennifer Cable, Siddharth Balachandran, Lisa P Daley-Bauer, et al.
American Journal of Human Genetics|June 19, 1998
Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international studyS L Neuhausen, A K Godwin, R Gershoni-Baruch, et al.
JCO Precision Oncology|October 16, 2024
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyFrancis P Worden, Evan Pisick, Michael Rothe, et al.
Cancer Cell|January 9, 2026
Framework for cancer evolution profiling and interception in colorectal cancer: ASCEND-CRC programSalvador Alonso, Kanwal Raghav, Van K Morris, et al.
JCO Precision Oncology|October 16, 2025
Olaparib in Patients With Solid Tumors With <i>BRCA1/2</i> Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) StudyTareq Al Baghdadi, Michael Rothe, Pam K Mangat, et al.
Pageof 42

Showing results (401-410 of 418) with videos related to

Sort By:
Pageof 42
Physiological Genomics|December 13, 2018
Identification of molecular signatures of cystic fibrosis disease status with plasma-based functional genomicsHara Levy, Shuang Jia, Amy Pan, et al.
JCO Precision Oncology|December 14, 2023
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry StudyFunda Meric-Bernstam, Michael Rothe, Pam K Mangat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2024
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With <i>ERBB2/3</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyTimothy L Cannon, Michael Rothe, Pam K Mangat, et al.
MMWR. Morbidity and Mortality Weekly Report|October 19, 2018
Notes from the Field: Contact Tracing Investigation after First Case of Andes Virus in the United States - Delaware, February 2018Aaron Kofman, Paula Eggers, Anne Kjemtrup, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2023
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry StudyHerbert L Duvivier, Michael Rothe, Pam K Mangat, et al.
Annals of the New York Academy of Sciences|January 31, 2023
Viral immunity: Basic mechanisms and therapeutic applications-a Keystone Symposia reportJennifer Cable, Siddharth Balachandran, Lisa P Daley-Bauer, et al.
American Journal of Human Genetics|June 19, 1998
Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international studyS L Neuhausen, A K Godwin, R Gershoni-Baruch, et al.
JCO Precision Oncology|October 16, 2024
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyFrancis P Worden, Evan Pisick, Michael Rothe, et al.
Cancer Cell|January 9, 2026
Framework for cancer evolution profiling and interception in colorectal cancer: ASCEND-CRC programSalvador Alonso, Kanwal Raghav, Van K Morris, et al.
JCO Precision Oncology|October 16, 2025
Olaparib in Patients With Solid Tumors With <i>BRCA1/2</i> Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) StudyTareq Al Baghdadi, Michael Rothe, Pam K Mangat, et al.
Pageof 42